Aratana Therapeutics
Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for dogs and cats in the United States. Founded in 2010 and based in Leawood, Kansas, the company offers a range of products including NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for osteoarthritis pain and inflammation. Additionally, it is advancing several therapeutic candidates, such as a bupivacaine liposome injectable suspension for cats, a formulation of capromorelin for appetite stimulation in cats, and treatments for atopic dermatitis and feline herpes virus. Aratana collaborates with other organizations, including Elanco Animal Health and Pacira Pharmaceuticals, to enhance its product development and commercialization efforts. The company aims to address unmet needs in companion animal healthcare by leveraging proprietary technologies and scientific advancements.
Okapi Sciences
Acquisition in 2014
Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics for pets and livestock. It operates a proprietary platform dedicated to creating innovative treatments for significant viral diseases, with five candidates currently in clinical or development stages. The company specializes in addressing viral infections affecting pets, particularly through its work on feline herpes and feline immunodeficiency virus. Okapi Sciences is committed to advancing its pipeline of antiviral drugs while fostering strong relationships with academic institutions to enhance its research capabilities and technological advancements in veterinary medicine.
Vet Therapeutics
Acquisition in 2013
Vet Therapeutics is developing antibody-based therapies to treat pet cancer and chronic conditions. The company is committed to bringing the same modality of products that constitute the standard of care in humans to animal health by applying world-class science to new products for companion animals. The Vet Therapeutics team has more than 30 years' experience and a successful track record at developing antibody-based biologics for humans, which is directed towards the development of pet-specific biologics to treat pet cancer and chronic conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.